Introduction
Systemic lupus erythematosus (SLE) is a prototypical systemic autoimmune disease that represents a great challenge for current therapy as well as new drug development (1, 2) . Despite intensive effort, only one therapy, belimumab, has been approved by the Food and Drug Administration (FDA) for SLE in the last 50 years. Other agents such as rituximab and mycophenolate mofetil, while extensively used in the clinic, nevertheless failed to meet criteria for regulatory approval in randomized clinical trials (3) (4) (5) . The slow pace of drug development has raised fundamental questions about designing trials and measuring responses for this complicated disease (6, 7) .
Among various aspects of lupus clinical trial design currently under consideration, an important one is the role of laboratory biomarkers to identify patients who are most appropriate for such studies and their likelihood of responding to new therapy. The expression of a biomarker could potentially predict a response if its presence fortifies the diagnosis, signifies relevant disease activity (and thus potential for modulation), or points to the operation of a mechanism that may be specifically targeted by the agent investigated. Since lupus is highly heterogeneous in terms of clinical manifestations, genetics, and underlying pathogenetic disturbances, an initial focus on a more limited population defined by a clinical or laboratory marker may facilitate detection of a treatment response in a clinical trial.
Among the many biomarkers for lupus, antinuclear antibodies (ANAs) and anti-DNA antibodies are already in use as entry criteria for many clinical trials of new agents. The use of serologic biomarkers for this purpose developed as a consequence of the phase II experience with belimumab, a monoclonal antibody to B lymphocyte stimulator/BAFF (TNFSF13B) (8) . Following failure of the trial to meet its primary end points, a post hoc analysis revealed that the subset of autoantibody-positive subjects did achieve significant therapeutic benefit. This finding suggested that this patient subset might be appropriate for B cell-directed therapy, a point perhaps substantiated by the success of the phase III trials, which required autoantibody positivity as an entry criterion (9) (10) (11) .
Based on the results of the belimumab trials, autoantibody-positive patients have become the standard group studied in clinical trials, not just for B celldirected therapies but more generally for immunomodulatory agents. In the absence of decisive data indicating a more robust response of such patients to therapy, the rationale for this approach has been uncertain. Furthermore, while biomarker-based subsetting has been generally adopted by sponsors, the biomarkers in question have not been qualified by the FDA for this purpose.
The use of a biomarker as an entry criterion for lupus clinical trials raises important questions about the validity, reliabity, stability, and pathogenic importance of the specific serologic marker employed. These questions are profound. Does the likelihood of treatment response depend on the presence of a biomarker expressed by a patient at trial enrollment? Do currently available assays reliably and reproducibly detect the biomarker for predicting treatment response? Does the expression of the biomarker change over time, necessitating repeat testing during the course of disease, including trial entry? Most pertinent, are clinical manifestations of lupus dependent on the biomarker, or is there a component of lupus that is independent of the pathway revealed by the biomarker?
As biomarker-based subsetting could represent an important step on the path to personalized or precision treatment for lupus, this review will consider, as an important example, the role of serologic biomarkers as entry criteria for clinical trials of potential new agents in lupus. The experience with ANA and anti-DNA testing is already considerable and provides an important new perspective on the information content, performance characteristics, and reliability of existing biomarkers. An important objective of this review is to encourage further development and refinement of biomarker assays and possibly regulatory guidance to facilitate the conduct of lupus trials in the future.
Types of biomarkers
While the term biomarker is commonly used as if it denoted a single entity, biomarkers are in fact diverse, differing in information content and significance (Table 1) . Among these categories, a biomarker that can identify the likelihood of a treatment response represents a prognostic biomarker. In other terminology, such a marker can be considered a theranostic or predictive marker; a companion diagnostic is another designation. Markers of this kind can be used to help select patients for trials by identifying those likely to respond to either therapy in general or to a specific class of agents. The use of predictive biomarkers has advanced farthest in oncology because of the identification of genetic mutations or physiologic markers, such as checkpoint inhibitor ligands in the tumor tissue, to be targeted by new agents. Depending on the strength of the data emerging from clinical trials, such markers could inform the eventual use of new agents in the clinic, an objective that depends on trial design, the characteristics of the marker, the reliability and reproducibility of its assay, and its performance at local as well as central laboratories (12, 13) .
The use of ANA and anti-DNA as prognostic markers in lupus originated with the phase III Study of Belimumab in Subjects with SLE (BLISS) trials of belimumab. For trial entry, in addition to other measures of disease activity, patients had to have serologic evidence of lupus, defined as ANA positivity at a titer of $1:80 or positive anti-DNA antibody at a level of .30 IU/ml. While anti-DNA is one of the most specific markers in lupus, the ANA is among the least specific. For ANA, the issues in its use as a theranostic are more vexing since the nonspecificity of this test has constrained its use in any of the categories listed in Table 1 ; in contrast, anti-DNA has utility in all contexts (14) (15) (16) .
ANAs
The determination of ANA positivity by an indirect immunofluorescence (IIF) assay as an entry criterion for a clinical trial in lupus may seem odd in view of prevailing ideas of ANA expression in SLE. While frequently present in normal individuals, ANAs nevertheless represent a serologic criterion for the classification of patients with lupus, and it is generally believed that patients with SLE almost invariably express ANAs of some specificity. To the extent that it may exist, ANAnegative lupus has been considered to be rare (17) . Nevertheless, even though 95-99% of patients with lupus are thought to be ANA positive, current ANA positivity (as opposed to historic ANA positivity determined in routine care) has surprisingly emerged as a biomarker for selecting patients for trial entry.
There are a number of reasons that ANA positivity could be useful in the trial setting. The first is to assure the diagnosis of lupus. Many trials of new agents are performed in patients who are considered to have "generalized lupus," often limited to skin and musculoskeletal involvement. With involvement of only 2 organ systems, the documentation of active lupus can be challenging. Therefore, to increase the likelihood of an accurate diagnosis, the ANA has been employed as an entry criterion. It is important to note that, although few studies have explored the sensitivity and specificity of the ANA in this setting, many trials have adopted this approach. Given uncertainty in laboratory testing in various clinical settings where patients are enrolled, the presence of current seropositivity as determined at a central laboratory is thought to provide support for the diagnosis. Again, few studies have examined the utility of the ANA test for this purpose.
A second reason for considering ANA positivity as a criterion for trial entry relates to the putative roles of (22) . Furthermore, since production of autoantibodies is often T cell dependent, abnormalities in follicular Th cells might be implied. In this regard, the ANA may identify a subset of patients who are more likely to have disease pathogenesis mediated by B cell-, T cell-, and/or TLR-mediated processes. This use of ANA-dependent subsetting could be considered an attempt at personalized or precision medicine, although the validity of this approach has not been rigorously tested. While these considerations provide a rationale for ANA positivity as a criterion for trial entry, they do not explain the high frequency of negative serology observed in the screening of patients for trials. This frequency has been as high as 20-30% (23) . For a clinical development program, a high frequency of screen failures is costly in time and money and can slow recruitment. A larger question thus looms-why should so many people with putatively active lupus apparently lack ANA expression?
There are 3 possible reasons for the high frequency of seronegativity among patients screened for trials. First, the patients who are ANA negative in screening may never have had lupus despite some consistent clinical findings; the explanation is a matter of misdiagnosis or misclassification. Second, while a patient may have once been serologically positive, he or she may no longer express an ANA at the time of screening. This change could reflect the natural history of disease or the effects of agents that have an impact on B cells (e.g., cyclophosphamide or mycophenolate mofetil). Third, the finding of seronegativity at the time of screening may be an issue involving the assay, with a historical positive result being a true-positive and the result during screening being a false-negative. In this scenario, assay variability could be the culprit.
While lupus is thought to be almost invariably ANA positive, studies have shown that ANA negativity may be more common than usually thought and that serology can change over time, associated with loss as well as gain of autoantibodies (24) (25) (26) (27) (28) (29) . Since ANA testing is infrequently performed in routine practice for a patient with established disease, these shifts in serology may often go undetected; indeed, there is usually little clinical reason to revisit serology except for anti-DNA. Just as autoantibody production may increase in a preimmune state, it may shift and decrease in a "post-autoimmune" state following diagnosis and treatment.
The technical issues in ANA testing are also considerable, although the high frequency of positive results in the otherwise healthy population is usually considered the problem. In fact, IIF assay kits supplied by different manufacturers are not equivalent in detecting ANA positivity (30, 31) . Available assays differ in the properties of immunochemical reagents and tissue culture cell lines (including fixation) used for detecting autoantibody binding (32, 33) . ANA assays by enzyme-linked immunosorbent assay (ELISA) or multiplex technology also show variability depending on the choice of antigen preparation or construction of a multiplex antigen panel (34) .
Distinguishing between a loss of ANA expression and assay inconsistency is difficult, especially when clinical or reference laboratories use different kits. To provide some data on this issue, we performed pilot studies to investigate variability in serologic results in the testing of sera from a well-followed cohort of patients with lupus. We used a series of commercially available ANA kits to assay the sera of 103 patients, approximately half of whom had renal disease. With 3 commercially available kits, the frequency of positivity of these samples ranged from 68.9% to 93.2% (Pisetsky DS, Rovin BH: unpublished observations). These data illustrate that ANA negativity, as measured with different kits, occurs not infrequently among patients, a point that, while well reported in the literature, is often neither recognized nor acknowledged.
Anti-DNA
ANA expression is relatively nonspecific. In contrast, anti-DNA expression is highly associated with SLE and serves as a quite specific diagnostic marker (35, 36) . A rationale for its use as an entry criterion for a clinical trial thus appears more solid than that for an ANA, even though anti-DNA expression occurs variably among patients and changes over time. Thus, only 30-50% of patients with SLE ever express anti-DNA antibodies and levels can fluctuate dramatically, sometimes even disappearing in patients who previously had robust autoantibody titers (37, 38) . Furthermore, despite debates about its utility as a staging or prognostic marker, anti-DNA positivity is included as a measure of disease activity in indices such as the SLE Disease Activity Index (39) .
While anti-DNA has solid credentials for a theranostic marker, its assay can be difficult, which is related to the nature of DNA as an antigen. Even when double stranded, DNA is structurally diverse because of sequence microheterogeneity (40) . Correspondingly, anti-DNA antibodies vary in specificity and avidity. Since currently available assay kits differ in DNA source and assay conditions (e.g., salt concentration), a serum sample that is positive according to one anti-DNA antibody assay may be negative according to another; for a given patient, however, an assay usually can produce consistent results over time, allowing sequential autoantibody determinations to be used as a biomarker for disease activity (41) .
The best assay for anti-DNA testing is a matter of debate and, while some studies have posited a classic Farr assay as the "gold standard," that assessment is primarily based on the setting of diagnosis, where a Farr assay has high specificity despite low sensitivity. The Farr assay is difficult to obtain at present because of its use of radioactivity, and, as shown in many studies, it can detect only some anti-DNA specificities. Even if the Farr assay were more widely available, its use as a theranostic could be limited by its low sensitivity. Review of the literature indicates the striking differences among assay formats for anti-DNA testing when comparing results from assays such the Crithidia luciliae IIF assay, ELISA, and Farr assay, among other formats (42) (43) (44) (45) (46) (47) .
Together, these results indicate that the use of results of a current anti-DNA assay for screening could have significant consequences for determination of trial eligibility, especially in the absence of data as to which of the existing assays has the greatest utility in the theranostic setting as opposed to the diagnostic setting. Certainly, the serum of a patient with active lupus could be bona fide positive with one anti-DNA assay but negative with another. Depending on other clinical and laboratory features, such a patient could be ineligible for a trial if the particular anti-DNA assay used for screening did not detect that patient's autoantibody.
Recommendations
Lupus is a disease that is marked by flares and often unexplained and unpredictable changes of disease activity. Not surprisingly, the expression of biomarkers may vary over time, complicating their use in the setting of clinical trials. The experience with anti-DNA and ANA testing is likely but the first example of the vagaries of predictive biomarkers in lupus. With the use of other biomarkers as entry criteria for trials the same challenges may be encountered, making it important to develop a conceptual and practical framework to incorporate their use into the trial setting (see Table 2 ) in contrast to routine clinical care.
In view of the shifting serologic profile of patients with SLE and the technical difficulties in ANA and anti-DNA measurement, there are several approaches to the use of serology to determine trial eligibility. The first differs from the current approach and would consider for trials anyone with active lupus who has met classification criteria, including serologic positivity, at some point in time irrespective of current serology at screening. This approach acknowledges the inherent difficulties in serologic testing and places strong emphasis on clinical and laboratory findings, along with judgment of the physician, as evidence of disease activity. Such an approach corresponds to real-world experience, where changes in therapy are made irrespective of ANA status.
In contrast to a more nihilistic approach to serologic screening, the utilization of ANA and anti-DNA to identify treatment-responsive individuals is consistent with the postulated role of these autoantibodies in pathogenesis and with circumstantial evidence that their expression identifies patients with active, treatment-responsive disease. Studies in the setting of preautoimmunity and incomplete lupus have tried to delineate the relationship between expression of cytokines (including type I and type II IFNs) and autoantibody expression to determine which of the immunologic phenomena in lupus is primary (i.e., immune dysregulation or autoantibody production). While some cytokine disturbances (e.g., IFNg production) may be independent of autoantibodies, others (i.e., type I IFN production) seem dependent (48, 49) . In such a situation, a focus on antibody-positive patients would seem warranted to encompass more fully the range of immunologic disturbances that may underlie pathogenesis. If ANA positivity and anti-DNA positivity continue to be used as entry criteria in trials, existing data support the need for much greater standardization to allow comparison of patient populations as well as consistency in screening. Furthermore, the data suggest a need to reevaluate lupus serology more comprehensively to determine the longitudinal expression of markers, not just at the time of diagnosis but subsequently in the course of disease, especially when new treatment options, including entry into a trial, are considered (50) . Such a reevaluation can involve various ANA assay kits as well as ELISAs and other immunoassays for more specific antibodies (e.g., anti-RNA binding proteins such as anti-Sm and anti-RNP). This endeavor could also involve the creation of new biomarker platforms or the refinement of older ones to provide a better correlation with observed clinical responses and help substantiate their use as predictors or companion diagnostics. Reference to the study of new agents for cancer provides an approach for developing predictive markers whose validation must be rigorous and, indeed, may have to match the rigor of the validation of a new therapy, especially if the expression of the marker determines the use of the therapy (12, 13) . Such biomarkers can be tested as part of a codevelopment program that involves both the therapy and the diagnostic (51, 52) .
We think that ANA assays should be reported in a quantitative rather than a qualitative manner, since it is likely that the levels of autoantibody reflect the activity of pathogenic plasma cells and, via their influence on the amount of ICs formed, could affect the magnitude of the type I IFN response as well. Reporting results in a qualitative manner (ANA or anti-DNA) could limit detection of such quantitative effects that might have an impact on disease activity and therefore on potential responsiveness to a new agent.
Pending more information on the evolution (and devolution) of serologic responses in SLE, we would make two additional recommendations. The first is to encourage developers of clinical protocols or authors of publications to be specific about the ANA assay kits used in studies. In this way, it will be at least possible to compare populations entered into different trials. The second recommendation is to screen patients for trial entry with more than one assay kit or even format (e.g., IIF, ELISA, multiplex) to reduce the chance that the serologic status of a patient is misinterpreted.
For anti-DNA antibodies, we would recommend using more than one anti-DNA assay for screening to try to capture as many positive values as possible. Since a gold standard for diagnosis may not be a gold standard for staging, future studies could compare different anti-DNA assays to determine the best one for predicting (and assessing) treatment response. In this regard, the establishment of a "cutoff" value to determine anti-DNA positivity is most meaningful in the context of a specific assay format. It is important to note that in clinical trials as well as practice, anti-DNA positivity is frequently associated with depression of complement values, likely because of the presence of ICs. As shown in some studies, the combination of anti-DNA positivity and low complement may more accurately identify a subset of patients who are likely to respond to therapy (11) . The addition of a low complement value could thus augment the information provided by anti-DNA testing.
In developing new therapies for lupus, there is keen interest in the use of other biomarkers (e.g., IFN signature, flow cytometric analysis of plasma cells/plasmablasts) to identify patients who are likely to respond to specific agents. Markers like the IFN signature may point directly to pathways that can be blocked by agents directed to a cytokine or cytokine receptor; in contrast, heightened B cell activity as manifested by an increased number of circulating plasma cells/plasmablasts may lead to the consideration of a variety of agents whose ultimate effect is to attenuate B cell activation or differentiation (53) (54) (55) (56) . While linking a biomarker to a therapeutic target is an important goal, the biomarker itself must meet high standards of reliability and reproducibility and involve well-validated methodology. As consideration of ANA and anti-DNA testing indicates, the clinical trial setting is quite different from routine clinical care and may require serologic markers with distinct properties. Retrospective as well as prospective studies may indicate the properties needed to make a serologic biomarker into a theranostic.
Conclusions
The utilization of ANA and anti-DNA as entry criteria for clinical trials in lupus is potentially an important innovation in the development of personalized or precision approaches for the treatment of the disease, although it highlights the challenges in using biomarkers as predictive, theranostic, or companion biomarkers. Of the multitude of biomarkers explored in lupus, few if any have been validated for this purpose. Such validation will likely entail a complex and iterative process that may require consideration of trial design as well as testing of various assays for the same laboratory finding (e.g., IFN signature). While this approach may have led to success in the development of belimumab, supporting data on its applicability to other agents are limited. These considerations suggest some pragmatic recommendations that may be useful in the near term and point to the value of exploring in greater depth the expression of two of the most venerable and consequential biomarkers in all of medicine.
